A phase 1 trial of a CAR T cell therapy targeting GPC3 in patients with HCC that have progressed following surgery, locoregional therapy, or systemic therapy did not yield results similar to those of other modalities targeting GPC3, with the majority of patients experiencing progression of disease leading to an ORR of 15%; among the two patients that received prior sorafenib, one experienced stable disease, and the other progression [130]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.